Lintuzumab satetraxetan AC-225

DB15053InvestigationalProtein Based Therapies

Lintuzumab actinium Ac-225 is under investigation in clinical trial NCT00672165 (Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies).

Mechanism: Pharmacologically active on Myeloid cell surface antigen CD33
Curator reviewed
Also known as: 225Ac-HuM195 · 225Ac-lintuzumab · Actinium (225ac) lintuzumab satetraxetan · Actinium AC 225 lintuzumab · Actinium AC-225 lintuzumab
Code names: SGN-33 AC-225

Resolves to

Compound

UNIIV860J30J9NCAS2209911-94-2

Targets

P20138CD33

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lintuzumab satetraxetan AC-225, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account